GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Rohto Pharmaceutical Co 4527.T · JPY

Consumer Staples · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

2,780

+3.12%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥343.73bn

FY2017FY2026

Net income

¥34.25bn

FY2017FY2026

Free cash flow

¥36.29bn

FY2017FY2026

Shareholders' equity

¥301.83bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥343.73bn¥308.63bn¥270.84bn¥238.66bn¥199.65bn¥181.05bn¥188.38bn¥183.67bn¥171.79bn¥154.60bn
Gross profit¥182.96bn¥169.46bn¥154.93bn¥135.13bn¥114.10bn¥104.96bn¥112.70bn¥108.32bn¥99.77bn¥90.01bn
Research and development¥13.73bn¥14.99bn¥13.46bn¥11.12bn¥8.78bn¥7.94bn¥7.08bn¥6.91bn¥6.58bn¥6.15bn
Operating income¥48.10bn¥38.47bn¥40.17bn¥33.54bn¥27.86bn¥21.87bn¥22.88bn¥20.55bn¥18.75bn¥15.45bn
Net income¥34.25bn¥31.00bn¥30.94bn¥26.38bn¥21.13bn¥16.74bn¥15.41bn¥9.80bn¥9.29bn¥10.01bn
Diluted earnings per share149.52130.71135.22115.2992.3573.3967.5442.9640.7543.94

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥485.77bn¥421.88bn¥346.18bn¥309.68bn¥269.08bn¥225.79bn¥215.30bn¥200.95bn¥200.84bn¥181.54bn
Cash and short-term investments¥86.82bn¥77.16bn¥89.21bn¥79.95bn¥72.79bn¥52.96bn¥45.31bn¥37.86bn¥30.53bn¥23.92bn
Total liabilities¥165.59bn¥150.43bn¥99.14bn¥94.60bn¥90.80bn¥69.18bn¥75.27bn¥68.77bn¥72.40bn¥63.11bn
Debt¥60.24bn¥61.23bn¥12.81bn¥12.88bn¥21.38bn¥8.28bn¥7.57bn¥5.23bn¥5.92bn¥5.12bn
Shareholders' equity¥301.83bn¥260.10bn¥246.33bn¥209.57bn¥178.28bn¥155.91bn¥139.28bn¥131.27bn¥127.68bn¥118.00bn
Shares outstanding229m237m229m229m229m228m228m228m228m228m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations¥47.79bn¥36.92bn¥34.24bn¥30.92bn¥27.25bn¥20.01bn¥19.04bn¥21.75bn¥19.15bn¥13.43bn
Capital spending−¥11.49bn−¥9.08bn−¥7.98bn−¥8.47bn−¥10.27bn−¥8.72bn−¥5.59bn−¥6.42bn−¥5.00bn−¥3.78bn
Free cash flow¥36.29bn¥27.84bn¥26.27bn¥22.45bn¥16.98bn¥11.29bn¥13.45bn¥15.33bn¥14.15bn¥9.65bn
Dividends paid−¥9.26bn−¥7.07bn−¥5.47bn−¥4.68bn−¥3.42bn−¥2.96bn−¥3.08bn−¥2.51bn−¥2.51bn−¥2.28bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥91.62bn¥90.65bn¥88.81bn¥82.29bn¥81.96bn¥82.73bn¥86.81bn¥70.73bn
Gross profit¥51.05bn¥49.85bn¥50.62bn¥44.83bn¥45.35bn¥45.26bn¥49.76bn¥39.34bn
Operating income¥13.66bn¥7.47bn¥14.11bn¥7.50bn¥11.63bn¥6.55bn¥14.05bn¥5.94bn
Net income¥10.65bn¥5.97bn¥10.63bn¥5.88bn¥11.77bn¥6.20bn¥11.82bn¥4.44bn
Diluted earnings per share46.5026.0644.8024.8149.6126.1451.6819.39
Total assets¥487.15bn¥485.77bn¥460.67bn¥439.90bn¥428.33bn¥421.88bn¥403.86bn¥408.26bn
Cash and short-term investments¥84.77bn¥86.82bn¥74.10bn¥78.24bn¥75.84bn¥77.16bn¥61.71bn¥64.50bn
Debt¥22.14bn¥52.93bn¥25.03bn¥47.08bn¥6.84bn¥54.05bn¥21.02bn¥44.54bn
Shareholders' equity¥309.49bn¥301.83bn¥287.46bn¥275.19bn¥266.74bn¥260.10bn¥256.07bn¥253.04bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.9%13.7%7.5%
Operating income12.8%17.1%11.9%
Net income9.1%15.4%14.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin54.0%55.3%55.9%56.9%
Operating margin13.3%13.8%13.6%12.6%
Net margin10.0%10.5%10.4%8.9%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings19.120.121.324.725.123.722.638.636.834.3
Price to sales1.92.02.42.72.72.21.92.12.02.2

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year25.0066.0031.0024.0020.5014.5013.0013.50
  • 2-for-1 split · 29 Dec 2022
  • 2-for-1 split · 27 Sept 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.